Progressive Pulmonary Fibrosis clinical trials

Explore recruiting progressive pulmonary fibrosis clinical trials.

Recruiting progressive pulmonary fibrosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Progressive Pulmonary Fibrosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF)

Belgium, Italy, Spain, France, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Tezepelumab (Anti-TSLP-mab) in progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia - A prospective two-armed, phase II clinical multicentre randomized, placebo-controlled (2:1), blinded with open-label extension trial (TEFIBEOS)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

PET/CT imaging with FAPI as a biomarker for the distinction between predominant active fibrotic and inflammatory phenotypes in patients with progressive pulmonary fibrosis: The FIBRO-PET study.

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis

Denmark, Portugal, Netherlands, Finland, Germany, Italy +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Subjects with Progressive Pulmonary Fibrosis (PPF)

France, Germany, Italy, Spain, Poland, Netherlands +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

PET/CT imaging with FAPI as a biomarker for the distinction between predominant active fibrotic and inflammatory phenotypes in patients with progressive pulmonary fibrosis: The FIBRO-PET study.

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Progressive Pulmonary Fibrosis trials by city

Progressive Pulmonary Fibrosis in Toronto Progressive Pulmonary Fibrosis in Vancouver Progressive Pulmonary Fibrosis in Montreal Progressive Pulmonary Fibrosis in Calgary Progressive Pulmonary Fibrosis in Edmonton Progressive Pulmonary Fibrosis in Ottawa Progressive Pulmonary Fibrosis in Winnipeg Progressive Pulmonary Fibrosis in Quebec City Progressive Pulmonary Fibrosis in Hamilton Progressive Pulmonary Fibrosis in Kitchener Progressive Pulmonary Fibrosis in London Progressive Pulmonary Fibrosis in Halifax Progressive Pulmonary Fibrosis in New York Progressive Pulmonary Fibrosis in Los Angeles Progressive Pulmonary Fibrosis in Chicago Progressive Pulmonary Fibrosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease